Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of “Moderate Buy” from Analysts

Entrada Therapeutics, Inc. (NASDAQ: TRDA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and one